317 related articles for article (PubMed ID: 16272086)
1. Biodefense. Critics question proposed countermeasures agency.
Kaiser J
Science; 2005 Nov; 310(5749):755. PubMed ID: 16272086
[No Abstract] [Full Text] [Related]
2. Biodefense. House passes plan for drug, vaccine R&D.
Kaiser J
Science; 2006 Oct; 314(5796):39. PubMed ID: 17023625
[No Abstract] [Full Text] [Related]
3. Bioterrorism. BioShield is slow to build U.S. defenses against bioweapons.
Kaiser J
Science; 2006 Jul; 313(5783):28-9. PubMed ID: 16825542
[No Abstract] [Full Text] [Related]
4. Throwing money at biodefense.
DeFrancesco L
Nat Biotechnol; 2004 Apr; 22(4):375-8. PubMed ID: 15060542
[No Abstract] [Full Text] [Related]
5. Biodefense. U.S. agencies unveil plan for biosecurity peer review.
Couzin J
Science; 2004 Mar; 303(5664):1595. PubMed ID: 15016970
[No Abstract] [Full Text] [Related]
6. Agency set up to tackle bioterror.
Wadman M
Nature; 2006 Dec; 444(7121):796-7. PubMed ID: 17167438
[No Abstract] [Full Text] [Related]
7. Research funding. U.S. biodefense boom: eight new study centers.
Malakoff D
Science; 2003 Sep; 301(5639):1450-1. PubMed ID: 12970522
[No Abstract] [Full Text] [Related]
8. Bioterrorism. Congress adopts tough rules for labs.
Malakoff D
Science; 2002 May; 296(5573):1585-7. PubMed ID: 12040151
[No Abstract] [Full Text] [Related]
9. Biodefense. Has biodefense gone overboard?
Enserink M; Kaiser J
Science; 2005 Mar; 307(5714):1396-8. PubMed ID: 15746402
[No Abstract] [Full Text] [Related]
10. Washington Report. Conflicting remedies for the National Institutes of Health.
Greenberg DS
N Engl J Med; 1979 May; 300(21):1231-2. PubMed ID: 431679
[No Abstract] [Full Text] [Related]
11. Management operations of the National Cancer Institute that influence the governance of science.
Natl Cancer Inst Monogr; 1984 May; 64():1-139. PubMed ID: 6749243
[No Abstract] [Full Text] [Related]
12. Managing science. House votes to kill grants, limit travel to meetings.
Kaiser J
Science; 2004 Sep; 305(5691):1688. PubMed ID: 15375232
[No Abstract] [Full Text] [Related]
13. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
14. Confidentiality of research grant protocols.
Morgan TE; Keyes JA; Sherman JF
Clin Res; 1976 Jan; 24(1):5-12. PubMed ID: 10277868
[No Abstract] [Full Text] [Related]
15. National Institute of Allergy and Infectious Diseases Challenge Grants designed to spark development of drugs to combat infectious diseases.
SoRelle R
Circulation; 2000 Oct; 102(15):E9030-1. PubMed ID: 11183866
[No Abstract] [Full Text] [Related]
16. Homeland security. New agency contains strong science arm.
Malakoff D
Science; 2002 Nov; 298(5598):1534. PubMed ID: 12446877
[No Abstract] [Full Text] [Related]
17. FY 1981 research and demonstration grants.
Health Care Financ Rev; 1981 Dec; 3(2):101-5. PubMed ID: 10309555
[No Abstract] [Full Text] [Related]
18. Access to NIH-funded research information--public comment period to November 16, 2004.
James JS
AIDS Treat News; 2004 Sep; (405):7-8. PubMed ID: 15595153
[TBL] [Abstract][Full Text] [Related]
19. A dose of reality for the health watchdogs.
Kluger J
Time; 2001 Oct; 158(19):65-6. PubMed ID: 11699134
[No Abstract] [Full Text] [Related]
20. Public Health and biosecurity. The limits of government regulation of science.
Kraemer JD; Gostin LO
Science; 2012 Mar; 335(6072):1047-9. PubMed ID: 22267583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
